Does APREPITANT Cause Malignant neoplasm progression? 28 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 28 reports of Malignant neoplasm progression have been filed in association with APREPITANT (CINVANTI). This represents 0.5% of all adverse event reports for APREPITANT.
28
Reports of Malignant neoplasm progression with APREPITANT
0.5%
of all APREPITANT reports
16
Deaths
11
Hospitalizations
How Dangerous Is Malignant neoplasm progression From APREPITANT?
Of the 28 reports, 16 (57.1%) resulted in death, 11 (39.3%) required hospitalization, and 4 (14.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for APREPITANT. However, 28 reports have been filed with the FAERS database.
What Other Side Effects Does APREPITANT Cause?
Fatigue (955)
Pyrexia (913)
Dyspnoea (909)
Hypersensitivity (881)
Rash (789)
Alopecia (760)
Gastrointestinal disorder (722)
Pruritus (707)
Confusional state (696)
Glossodynia (696)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which APREPITANT Alternatives Have Lower Malignant neoplasm progression Risk?
APREPITANT vs APROTININ
APREPITANT vs ARANESP
APREPITANT vs ARAVA
APREPITANT vs AREDIA
APREPITANT vs ARFORMOTEROL